Press Room

Press Clipping / Nov 12, 2018

How Hovione grew from a basement lab to a global pharmaceutical services company

C&EN, November 12, 2018

Global Pharmaceutical Services Diane Villax Guy Villax | Hovione

Diane Villax poses in 1962 with her husband, Ivan (left), and this year with her son, Guy, in front of the house, Guy’s current home, where she and Ivan launched Hovione in 1959.

 

 

Diane Villax, Hovione’s still-active matriarch, recounts the rise of the pioneering firm

He started, the poor chap, at the age of 23,” recalls Diane Villax of her son Guy’s debut in 1984 at Hovione, the family’s pharmaceutical chemical business. “He was thrown to the lions in the Far East. To China. He was told by his father, ‘Build me a factory in Macau. Get me some land, talk to the authorities, and build me a factory.”

This he did, she says. “He built it in 14 months, ran it for six months, and asked for an FDA inspection.”

Still marveling at the audacity of the project, Diane recounts the many roadblocks to building a factory in Macau, a former Portuguese colony, now a Las Vegas-like gaming resort, where no construction engineers were up to the project in 1984. Shipping construction materials, glass-lined tanks, and other apparatuses from Italy, Greece, and the company’s home base of Lisbon was another daunting challenge, given that the only suitable cargo port was in Rotterdam, the Netherlands.

Her daughter, Sofia, was also deployed to China, in charge of quality control at the new plant. Diane remembers Sofia calling home rattled after an interview with an inspector who brusquely dismissed the upstart plant’s chances of passing a U.S. Food & Drug Administration audit. “Poor child,” she says. “Well, they had the inspection, and it was fine, so then they all celebrated.”

Over a Saturday lunch of boiled prawns and salad on the patio of her home in a Lisbon suburb, Diane shares several other anecdotes of how she and her husband, the chemist Ivan Villax, started a company in their basement, developing fermentation processes for the manufacture of antibiotics. It has evolved over 59 years to become a major supplier of drug ingredients and associated services, with factories on three continents.

Ivan died in 2003, but at 83 Diane remains active with Hovione. She is a board member, having stepped down as chair only two years ago. Guy and Sofia are also on the board, along with four outside nonexecutive directors, including the current chair. Passing the chair to an outsider, Diane says, seemed like the thing to do now that the company has achieved a critical mass.

 

Born in Portugal but raised in England—her mother Portuguese, her father British—Diane Du Boulay met Ivan, a Hungarian chemist displaced by the Russian invasion after World War II, in 1956. Both their families had moved to Lisbon. Ivan came from France, where he studied microbiology, developing chemistry for penicillin, tetracycline, and other antibiotics in his spare time.

“I think he got his first patent in 1955,” Diane recalls. “He was enjoying life in Lisbon. A young man about town and a scientist and a bit of a magician at dinner parties. He was very much in demand.”

The two married and started the company with two partners, both of whom left shortly thereafter. Diane and Ivan began by selling antibiotics and other generic drugs, achieving their first big success selling betamethasone in Japan. They built a manufacturing plant on land his family owned outside Lisbon in Loures.

“Ivan was obviously the inventor, the producer, and the salesman,” she says. “Somebody had to look after the back office, issue invoices, talk to the banks, and get some money. So that was me. For 35 years, nobody signed a check except for me. I was in charge of all the imports and exports and all the licenses.”

The focus remained on generics, Diane says, until Guy came back from an InformEx exposition in the U.S. in 1993, enthusiastic about exclusive synthesis of active pharmaceutical ingredients (APIs). They got a call from Bristol-Myers Squibb shortly thereafter with a request to make an API, found a chemical engineer willing to take on the complicated chemistry, and never turned back.

Nor has Diane disengaged from oversight of the company’s business, which in one famous instance involved direct engagement with a chemical.

Early on, with Ivan on the road, Diane was awakened one night by a chemical smell in the house. She called an engineer who worked for the company, and the two identified a leaking vessel in the basement. They found an empty container. Preparing to transfer the contents of the vessel, Diane realized that someone would have to suck on the hose to get the liquid moving. The engineer demurred, noting that they had no idea what was leaking.

“I had to do it,” she says. “Somebody had to get it going.” The operation was a success, and Diane soon learned that the solvent was ethyl acetate. “My husband was rather horrified when he learned of this.”

Diane Villax was awarded Portugal’s Scientific Merit Medal at the opening of Science 2017, a science and technology meeting in Lisbon. The medal is given in recognition of contributions to the development of science and scientific culture in Portugal.

 

Read the article at C&EN online

 

 

Also in the Press Room

See All

Key Takeaways Commissioning a US-based ConsiGma CDC Flex line enables end-to-end spray drying-to-tablet manufacture within a single site and quality system, reducing comparability and technology-transfer burdens. Elimination of conventional scale-up is enabled by using the same equipment from early development through commercial supply, minimizing engineering runs and conserving scarce API. Operational flexibility spans batch or continuous modes and 1–200 kg/h throughput, with scale adjustment achieved by switching continuous blenders rather than replatforming processes. High-containment design to 1 µg/m³ expands suitability for highly potent oral solid-dose programs while maintaining integrated development-to-commercial workflows. Regulatory momentum for continuous manufacturing is supported by ICH Q13 harmonization, increasing FDA approvals, and platforms leveraging inline PAT and automated control suites for real-time quality assurance. Hovione announced on Oct. 5, 2026, that it will commission the ConsiGma CDC Flex, a next-generation continuous direct compression tableting platform jointly developed with GEA. The investment is designed to link amorphous solid dispersion manufacturing via spray drying with commercial tablet production at a single US site operating under one quality system. The line will run in either continuous or batch mode at throughputs from 1 to 200 kg/h. Formulation development can begin with as little as 1.5 kg of material, and the same equipment can then support everything from very small clinical batches to large commercial runs, enabled by a design that allows the system to switch between continuous blenders of different sizes. The installation will also be contained to 1 µg/m³ to accommodate highly potent compounds. "Hovione will be the first company in the world to offer the ConsiGma® CDC Flex, bringing this next-generation technology with unprecedented flexibility, simplicity and cost-efficiency in continuous tableting," said Marco Gil and António Almeida, co-CEOs, Hovione, said in a press release. "This investment also advances our strategy of building integrated capabilities close to customers in key markets. By adding this new line at East Windsor, we are broadening access to this technology in the U.S. and giving customers a more direct and accelerated path for developing and commercializing complex oral medicines." What Does a Single Development-To-Commercial Line Change? For formulators and process engineers, the most consequential claim is the removal of traditional scale-up. Moving a process from development equipment to commercial equipment typically requires engineering runs, bridging work, and consumption of scarce API, all of which weigh heavily on early programs with limited material. "Installing the CDC Flex at 89 Twin Rivers makes continuous tableting part of an integrated US development and manufacturing workflow," said David Basile, Vice President of Technical Operations, Hovione, in the press release. "Customers can move from formulation and particle engineering to commercial tablets with one Hovione team and one quality system, eliminating traditional scale-up while gaining greater production flexibility, process control and supply continuity." Co-locating spray drying and tableting is also significant because amorphous solid dispersions remain a primary solubility-enhancement route for poorly soluble molecules, and transferring intermediates between sites or vendors adds technology transfer and comparability burdens. The new line builds on the company's earlier US expansion; Hovione recently completed a $100 million investment to bolster US capacity in particle design, amorphous solid dispersions via spray drying, and batch and continuous tableting. How Is the Regulatory Environment Shaping Continuous Tableting Adoption? The company points to the 2022 adoption of ICH Q13, which provides harmonized guidance for continuous manufacturing of drug substances and drug products across the US, Europe, and Japan. Hovione reports that, as of 2024, FDA alone had approved 17 products manufactured under the guidance. Speaking on ICH Q13, FDA's Kelley Burridge, PhD, "Perceived barriers to continuous manufacturing have been falling one by one," and noted an FDA publication showing faster approval times for products with continuous manufacturing elements than for comparable batch products. The platform incorporates inline process analytical technology and automated controls for real-time quality monitoring, along with SimpleCT, an automation and control suite intended to support a single process from development through commercial supply. For sponsors weighing supply resilience and regional sourcing, the East Windsor installation extends a capability that Hovione says only it currently offers as a contract development and manufacturing organization.   Read the full article at PharmTech.com  

Press Clipping

Can Continuous Tableting End Scale-Up for Complex Oral Drugs?

Oct 05, 2026

The company is building out more than 200,000 square feet of space in New Jersey. In April, Contract Pharma had the opportunity to tour Hovione’s expanded manufacturing facility in East Windsor, NJ. The company is planning a formal ribbon-cutting this fall; before that, we got an inside look at some new features. Having established United States operations in 2002, Hovione now has more than 200,000 square feet of space in New Jersey. This will be developed into a large, integrated campus in the next five to ten years. Overall, the company’s recent NJ expansion, which began in 2025, has tripled its total spray-drying capacity in the U.S. Future Facility Upgrades A 125,000-square-foot greenfield acquired by Hovione at the East Windsor campus will eventually be a large-scale production site. This includes enhanced quality control and R&D capabilities. Together, all this adds to Hovione’s stable of manufacturing sites, R&D centers, and other offices spread across three continents. Key to the expansion is a targeted reduction of Hovione’s carbon footprint by 40% by the year 2030. Part of this goal is embracing new and/or changing solvent types to help meet sustainability standards. Additionally, the company says automation that has been put in place at its Portugal site will be replicated in NJ. Hovione Aligns NJ Operations At the Drug, Chemical & Associated Technologies Association (DCAT) Week in New York in March, Contract Pharma met with Hovione. There, David Basile, Vice President of Technical Operations—Americas, further illustrated the New Jersey expansion. “Hovione aims to build an equivalent manufacturing network, where clients can go to any site across the globe,” Basile said. “The design of the facility has been well-thought through with material flows [and] gravity-fed processes. It’s scalable. We call each one of these building segments a finger. You can copy and paste these fingers, and they are built to house both spray drying and drug product assets.” Ultimately, with these moves and a strategic partnership model, Hovione aims to provide customers an opportunity to co-invest and access the company’s proprietary knowledge and assets to accelerate programs and create long-term value. Read the full article at ContractPharma.com    

Press Clipping

Hovione Planning Ribbon-Cutting at NJ Facility – A Behind-the-Scenes Preview

Jul 31, 2026